7,215 Shares in Quanterix Corporation $QTRX Bought by State of Wyoming

State of Wyoming acquired a new position in shares of Quanterix Corporation (NASDAQ:QTRX) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 7,215 shares of the company’s stock, valued at approximately $47,000.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its stake in Quanterix by 18.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,878 shares of the company’s stock valued at $361,000 after acquiring an additional 5,385 shares during the last quarter. Northern Trust Corp lifted its holdings in Quanterix by 5.6% in the 4th quarter. Northern Trust Corp now owns 366,164 shares of the company’s stock valued at $3,892,000 after purchasing an additional 19,416 shares in the last quarter. Jane Street Group LLC grew its holdings in Quanterix by 18.1% in the 4th quarter. Jane Street Group LLC now owns 55,947 shares of the company’s stock valued at $595,000 after buying an additional 8,578 shares during the period. Ameriprise Financial Inc. increased its holdings in shares of Quanterix by 111.3% during the 4th quarter. Ameriprise Financial Inc. now owns 3,205,928 shares of the company’s stock worth $34,079,000 after buying an additional 1,688,680 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Quanterix by 756.5% during the 4th quarter. BNP Paribas Financial Markets now owns 64,896 shares of the company’s stock worth $690,000 after purchasing an additional 57,319 shares during the period. 86.48% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Wall Street Zen cut Quanterix from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Canaccord Genuity Group restated a “hold” rating and issued a $5.00 target price (down from $12.00) on shares of Quanterix in a research note on Monday, August 11th. One analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $11.75.

Insider Activity at Quanterix

In related news, Director David R. Walt acquired 123,990 shares of the firm’s stock in a transaction dated Friday, June 13th. The stock was acquired at an average cost of $6.14 per share, for a total transaction of $761,298.60. Following the completion of the acquisition, the director directly owned 1,866,933 shares of the company’s stock, valued at approximately $11,462,968.62. The trade was a 7.11% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 6.80% of the company’s stock.

Quanterix Trading Down 5.1%

Quanterix stock opened at $4.29 on Wednesday. The stock has a market cap of $199.36 million, a P/E ratio of -2.36 and a beta of 1.03. The stock has a 50 day moving average of $5.34 and a 200-day moving average of $5.80. Quanterix Corporation has a 52 week low of $4.05 and a 52 week high of $15.85.

Quanterix (NASDAQ:QTRX) last released its earnings results on Thursday, August 7th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. The business had revenue of $24.48 million for the quarter, compared to analysts’ expectations of $29.73 million. Quanterix has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Quanterix Corporation will post -0.98 earnings per share for the current fiscal year.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.